Shareholder Alert: Ademi LLP investigates whether Reata Pharmaceuticals, Inc. has obtained a Fair Price in its Private Placement and its transaction with Biogen

MILWAUKEE, July 28, 2023 /PRNewswire/ -- Ademi LLP is investigating Reata (Nasdaq: RETA) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Biogen. 

Click here to learn how to join the action https://www.ademilaw.com/case/reata-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Reata stockholders are expected to receive only $172.50, reflecting an enterprise value of approximately $7.3 billion. The transaction agreement unreasonably limits competing transactions for Reata by imposing a significant penalty if Reata accepts a competing bid. Reata insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Reata's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Reata common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/reata-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP